YIM Program Agenda
YIM Program
One of the goals of the iwCLL is to promote the development of emerging scientists, both clinic- and laboratory-based, who will continue to unravel outstanding questions in CLL. Since 2005, iwCLL has been preceded by a Young Investigator Meeting (YIM), which offers an opportunity for investigators less than 40 years of age to present and discuss their data.
The YIM is a forum for tomorrow’s leaders to network and collaborate with today’s CLL experts. Because of its relaxed atmosphere that facilitates interaction between emerging and established leaders in CLL,
“The purpose of the YIM is to facilitate the professional development of young clinical scientists in the field of CLL research. By providing an opportunity for young investigators to share their research interest in CLL, the YIM planners hope to promote their participation in the iwCLL and encourage their interaction with established senior CLL scientists and investigators to help advance their careers.”
–Shih-Shih Chen, PhD; 2019 YIM Co-Chair
| Friday, 20 September | |||
|---|---|---|---|
| 07:30 |
Breakfast Tea & Coffee | ||
| 08:00 | Welcome and Introductions | ||
| 08:05 |
Session 1: CLL Biology and Translational Research Chair(s): Ingo Ringshausen, Shih-Shih Chen, Talha Munir, Matthew Davids |
||
| 08:10 | 2049/2205: Analyzing the mutational landscape of two CLL mouse models overexpressing AID identifies proliferative fraction-associated tumor genes involved in leukemic development and progression Pablo Morande |
||
| 08:25 | 2168: Comparison of Genomic Complexity Risk Stratification by Chromosome Banding Analysis and Genomic Microarrays in CLL Patients With Complex Karyotype Silvia Ramos |
||
| 08:40 | 2011: Characterization of therapeutic resistance in chronic lymphocytic leukemia using functionalized lineage tracing Catherine Gutierrez |
||
| 08:55 | 2164: Therapeutically inducing interferon signaling in T cells with avadomide enhances the efficacy of anti-PD-L1/PD-1 immunotherapy in chronic lymphocytic leukemia Nikolaos Ioannou |
||
| 09:10 | 2020: Ikzf3 mutation dysregulates B cell receptor signaling and migratory responses in a conditional knock-in mouse model Elisa ten Hacken |
||
| 09:25 | 2074: Functional evaluation and mechanism study of circ-RPL15 as a plasma biomarker and novel oncogenic driver to promote progression of chronic lymphocytic leukemia Yi Xia |
||
| 09:40 | 2060: Combined ibrutinib and venetoclax changes myeloid immune phenotype and improves immune function in CLL patients Eva Rebecka Svanberg |
||
| 09:55 | Morning Break | ||
| 10:20 |
Session 2: Clinical Research Chair(s): Othman Al-Sawaf, Philip Thompson, Nitin Jain |
||
| 10:25 | 2064: The Role of 18F-FDG-PET in Detecting Richter’s Transformation of Chronic Lymphocytic Leukemia in Patients Receiving Therapy with a B-cell Receptor Inhibitor Yucai Wang |
||
| 10:40 | 2117: Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia Paul Hampel |
||
| 10:55 | 2134: Second primary malignancies (SPM) and Richter’s transformations in treated and untreated patients with chronic lymphocytic leukemia (CLL): an analysis of the registry of the German CLL Study Group (GCLLSG) Moritz Fürstenau |
||
| 11:10 | 1941/2206: Pneumocystis jirovecii pneumonia and invasive fungal infection incidence and institutional prophylaxis practices in CLL patients treated with BTK inhibitors Christine Ryan |
||
| 11:25 | 2056: Minor mutations in TP53 associate with shorter PFS but not OS after chemoimmunotherapy – Results from the Complement2 trial Eugen Tausch |
||
| 11:40 | 2089/2207: Undetectable Minimal Residual Disease Should be the Goal of Venetoclax Therapy in Relapsed and Refractory Chronic Lymphocytic Leukaemia Thomas Lew |
||
| 11:55 | Lunch | ||
| CONCURRENT BOOTCAMP SESSIONS |
|||
| Basic Biology Investigator Bootcamp Chair(s): Ingo Ringshausen, Shih-Shih Chen, Nicholas Chiorazzi |
|||
| 13:00 | Poster Presentations From the Podium | ||
| 2083: Gene Expression and Cytokine Analyses Identify Markers of Progression from MBL to CLL Gonzalo Blanco |
|||
| 2095: Dissecting the role of Toll-like receptors induced IkBz over-expression in Chronic Lymphocytic Leukemia Ilenia Sana |
|||
| 2193/2208: IL10-producing CD38hi B-regulatory cells drive the immunosuppressive microenvironment in CLL and can be targeted with anti-CD38 immunotherapy Alak Manna |
|||
| 2200: Chronic lymphocytic leukemia cells impair mitochondrial fitness in T cells which can be rescued by CD40-stimulation of the CLL cells Fleur Peters |
|||
| 2096/2209: CD8+ T-cell exhaustion induced by leukemic cells mediates progression in Chronic Lymphocytic Leukemia (CLL) Isabel Jiménez |
|||
| 14:05 | Career Development Discussion | ||
| 14:45 | Afternoon Break | ||
| Translational Investigator Bootcamp Chair(s): Talha Munir, Matthew Davids |
|||
| 13:00 | Poster Presentations From the Podium | ||
| 2009: Pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor, is a favorable modulator of T-cell function in ex vivo studies of chronic lymphocytic leukemia (CLL) Scott Best |
|||
| 2099: Mass cytometry analysis of B cell receptor signalling in normal B and chronic lymphocytic leukaemia cells in peripheral blood Faten Yasin |
|||
| 2167: AID and LPL mRNA expression are useful additional markers that improve CLL-IPI prediction in progressor patients Angimar Uriepero |
|||
| 2062/2210: Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome Yucai Wang |
|||
| 1931: Overexpression of TCTP Induces Inferior Prognosis and Fludarabine-Resistance in Patients with Chronic Lymphocytic Leukemia Rui-ze Chen |
|||
| 14:05 | Career Development Discussion | ||
| 14:45 | Afternoon Break | ||
| Clinical Investigator Bootcamp Chair(s): Othman Al-Sawaf, Philip Thompson, Nitin Jain |
|||
| 13:00 | Poster Presentations From the Podium | ||
| 1999: Use of antibiotics and risk of chronic lymphocytic leukemia: a population-based case-control study Michael Asger Andersen |
|||
| 2082: Impact of Individual Comorbidities on Mortality and Causes of Death in Chronic Lymphocytic Leukemia Emelie Curovic Rotbain |
|||
| 2118: A novel simplified comorbidity score for chronic lymphocytic leukemia (CLL): a large multicenter retrospective cohort study of patients treated with ibrutinib and/or chemo-immunotherapy (CIT) Max Gordon |
|||
| 2054: Role of complex karyotype (CK) in patients with chronic lymphocytic leukemia (CLL): A systematic review and meta-analysis. Irbaz Bin Riaz |
|||
| 1990: Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients Joanna Rhodes |
|||
| 14:05 | Career Development Discussion | ||
| 14:45 | Afternoon Break | ||
| 15:00 | Keynote Presentation: Career Development John Seymour |
||
| 15:45 | Q & A | ||
| 16:00 | YIM Award and Concluding Remarks | ||
| 16:15 | Adjourn | ||
– Agenda subject to change